RCELNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as AVHHL
AVITA Medical, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$13.14+0.10 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $404.05M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
82.1%+5.4 pts over 5 years
Operating margin
-59.4%+407.0 pts over 5 years
Net margin
-67.8%+390.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.5% | – | +38.1% | – | |
| Gross profit | +6.6% | – | +39.1% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2019 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -144.0% | 799.7% | |
| Return on assets | – | – | -71.4% | |
| Current ratio | – | 5.38 | 0.57 | |
| Debt to equity | – | – | -2.58 | |
| Net debt to EBITDA | – | – | -0.81× | |
| Interest coverage | – | -945.5× | -8.5× | |
| Inventory turnover | – | – | 1.8× | |
| Capex to revenue | – | 18.7% | 1.4% | |
| Diluted shares | 670M | 16M | 28M |
Where the cash went
Fiscal 2020 to 2025, five years combined
AVITA Medical generated $166.76M from operations and spent $13.04M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$166.76M
Used
$13.04M
Capital expenditure$13.04M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-67.8%
×Asset turnover1.05×
×Equity multiplier-11.20×
=Return on equity, FY2025799.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -67.8% | 1.05× | -11.20× | 799.7% |
| FY2024 | -96.3% | 0.67× | 3.57× | -231.0% |
| FY2021 | -90.9% | 0.28× | 1.11× | -28.3% |
| FY2020 | -294.7% | 0.26× | 1.16× | -90.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$48.59M
- Cash generatingOperating cash flow above zero-$31.20M
- Return on assets improvedROA up on the prior year-55.4% → -61.0%
- Earnings backed by cashOperating cash flow above net income-$31.20M vs -$48.59M
- Less leverageLong-term debt to assets fell53.0% → 0.0%
- Better liquidityCurrent ratio rose2.83 → 0.57
- No dilutionShare count did not rise26M → 28M
- Gross margin improvedGross margin up on the prior year85.85% → 82.13%
- More efficientAsset turnover rose0.58 → 0.90